Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5505001 | 0.80 | HTT (0.36) | EPHX2DPP4 | |
| SCHEMBL5504092 | 0.78 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5507384 | 0.73 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18426735 | 0.73 | GRIN2D (0.65) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6009972 | 0.70 | GRIN1 (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21518431 | 0.69 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28913293 | 0.68 | GRIN2D (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3171549 | 0.67 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3171553 | 0.67 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL292647 | 0.67 | GRIN1 (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | GRIN2D 2807/4885GRIN3B 2492/4885GRIN1 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.